// App-Quantinova.ai

PB2003 : REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.

Researchers

Presenter

  • Rafael Fonseca

Principal Investigators

  • Eric Chinaeke

  • Niodita Gupta

  • Alex Fu

  • Tao Ran

  • Shuchita Kaila

Medical Centers

  • Mayo Clinic,Phoenix,États-unis

  • Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

  • Mayo Clinic, Phoenix, Arizona, United States

  • Janssen Scientific Affairs, LLC,Horsham,Vereinigte Staaten

  • Mayo Clinic, Phoenix, AZ

  • Medicine,Mayo Clinic,Phoenix,Verenigde Staten

  • Janssen Scientific Affairs, LLC,Horsham,États-unis

  • Mayo Clinic,Phoenix,Stati Uniti

  • Janssen Scientific Affairs, LLC,Horsham,États-unis

  • Janssen Scientific Affairs, Horsham, PA

  • Medicine,Mayo Clinic,Phoenix,Verenigde Staten

  • Mayo Clinic,Phoenix,Estados Unidos

  • Janssen Scientific Affairs, LLC,Horsham,États-unis

  • Janssen Scientific Affairs, LLC,Horsham,Vereinigte Staaten

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Sparsentan

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved